Multiple Sclerosis is an unpredictable disease that deteriorates the protective covering of the nerves, which causes poor nerve-to-nerve communication throughout the body. More than 2.3 million people worldwide have a diagnosis of MS. There are two main types of MS; Relapsing, where there are short distinct periods of worsening symptoms that may resolve, and Progressive, where symptoms get worse over time. There are a wide variety of symptoms that include vision loss, fatigue, impaired coordination, numbness, and pain. This disease unfortunately does not have a cure, but there are new treatments in the pipeline seeking to improve the lives of patient who suffer from this disease.
Novartis LOU064C12302
The goal of this study is to compare the efficacy and safety of remibrutinib versus
teriflunomide in participants with relapsing multiple sclerosis (MS). Both medications work
to reduce the nervous system damage associated with MS, however, their mechanisms
differ. Remibrutinib reduces the activation and proliferation of B cells that are directly
involved in the adverse immune response in MS, whereas teriflunomide blocks the
proliferation of T cells, another prominent player in the immune response in MS patients.
The study will consist of a screening period of up to 35 days to assess eligibility to continue
into the placebo-controlled phase. In the treatment phase, the participant will be
randomized to receive remibrutinib, teriflunomide, or a matching placebo. These
medications will be taken daily for up to 30 months (about 2 and a half years). Site visits will
occur If eligible, the participant has the option to rollover in to the open-label extension
portion of the study, where the participant would receive definite remibrutinib daily for up
to 5 years. Site visits will occur at month 1 and every 6 months thereafter.
Learn more: https://classic.clinicaltrials.gov/ct2/show/NCT05147220
Sanofi EFV17504
This study is designed to assess the safety and efficacy of the investigational medication
frexalimab (SAR441344) in adults age 18-55 with non-relapsing secondary progressive
multiple sclerosis (MS). The damage seen in MS is caused by immune cells that attack the
protective covering of nerves, called myelin, which impairs nerve function, leads to
formation of plaques in the brain, and causes the symptoms seen in the disease.
Frexalimab binds to these immune cells and stops them from transforming into their active
form, which inhibits them from damaging the myelin and thus prevents plaque formation
and preserves nerve function. The treatment period of this study is variable but is expected
to last approximately 27 to 51 months for each participant, with a minimum duration of 12
months. During this time, patients will be randomly assigned in a 2 to 1 ratio to receive
either frexalimab or placebo by IV infusion every four weeks for the duration of their
participation. Importantly, those who experience disease progression at 6 months will be
offered treatment with frexalimab without the possibility of placebo. The aim of this study is to develop the first FDA approved treatment specifically for non-relapsing secondary
progressive MS that can slow the progression of disability.
Learn more: https://classic.clinicaltrials.gov/ct2/show/NCT06141486
Sanofi EFC17919
This study is designed to compare the safety and efficacy of the investigational medication
frexalimab (SAR441344) to teriflunomide, a current standard of care treatment, in adults
age 18-55 with relapsing forms of multiple sclerosis (MS). The damage seen in MS is
caused by immune cells that attack the protective covering of nerves, called myelin, which
impairs nerve function, leads to formation of plaques in the brain, and causes the
symptoms seen in the disease. Frexalimab binds to these immune cells and stops them
from transforming into their active form, which inhibits them from damaging the myelin and thus prevents plaque formation and preserves nerve function. The treatment period of this study is variable but is expected to last between 20 and 40 months for each participant. During this time, patients will be randomly assigned to receive either IV frexalimab every 4 weeks along with a placebo taken orally each day, or IV placebo every 4 weeks with oral teriflunomide each day. The aim of this study is to develop an MS treatment that is more effective than currently available medications at reducing disease activity in the brain and alleviating symptoms that cause disability.
Learn more: https://classic.clinicaltrials.gov/ct2/show/NCT06141473
At NEICR all of our clinical trials (and procedures associated with them) come at no cost to you. There may be compensation to you for your time and travel. If you are interested in participating or have any questions, feel free to fill out the form below or give us a call at (203) 914-1903 for more information.